Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.soncn.2025.151843 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intratumoral Injection of R848 and Poly(I:C) Synergistically Promoted Antitumour Immune Responses by Reprogramming Macrophage Polarization and Activating DCs in Lung Cancer.
Clin Exp Immunol
March 2025
School of Medicine, Guizhou University, Guiyang 550025, China.
Introduction: Immunotherapy has rapidly become a primary treatment option for many lung cancer patients because of its success in treating this prevalent and deadly disease. However, the success of immunotherapy relies on overcoming the immunosuppressive tumour microenvironment, making remodelling this environment a potential strategy for lung cancer therapy. Research suggests that Toll-like receptor (TLR) agonists can impede tumour growth by promoting the conversion of tumour-associated macrophages into an M1-like state or enhancing dendritic cell development.
View Article and Find Full Text PDFUnleashing the power of peptides in prostate cancer immunotherapy: mechanism, facts and perspectives.
Front Pharmacol
February 2025
TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Prostate cancer, the second most common cancer in men, often progresses to castration-resistant prostate cancer despite androgen deprivation therapy. Immunotherapy, revolutionary in cancer treatment, has limited efficacy in prostate cancer due to its "cold tumor" nature. Peptides, with unique advantages, offer new hope.
View Article and Find Full Text PDFGlobal, Regional, and National Disease Burden and Prediction Analysis of Colorectal Cancer Attributable to Tobacco, Alcohol, and Obesity From 1990 to 2030.
Front Oncol
February 2025
Department of Health, Inspection and Quarantine, School of Public Health, University of South China, Hengyang, China.
Background: Colorectal cancer (CRC) ranks among the highest in incidence and mortality rates globally. A significant portion of Colorectal cancer cases and deaths can be attributed to modifiable risk factors, with smoking, alcohol use, and high body mass index (BMI) being the three most prominent. However, the impact of these risk factors on Colorectal cancer across regions, genders, and age groups remains insufficiently characterized.
View Article and Find Full Text PDFAdvances in Nanomaterials for Targeted Drug Delivery: Emerging Trends and Future Prospects in Nanodrug Development.
Curr Cancer Drug Targets
March 2025
Electrical Engineering Department, College of Engineering, King Khalid University, Abha, 61421, Saudi Arabia.
The development of targeted drug delivery systems has transformed modern medicine, offering novel approaches to improve the efficacy and safety of therapeutic agents. Nanomaterials, due to their unique physicochemical properties, have emerged as pivotal contributors to this transformation. This paper aimed to explore recent advance-ments in nanomaterials for targeted drug delivery, highlighting emerging trends and pro-spects in nanodrug development.
View Article and Find Full Text PDFHigh Mobility Group A1 Chromatin Keys: Unlocking the Genome During MPN Progression.
Int J Mol Sci
February 2025
Departments of Medicine (Hematology), Oncology, Pathology and Institute for Cellular Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Patients with chronic, indolent myeloproliferative neoplasms (MPNs) are at risk for transformation to highly lethal leukemia, although targetable mechanisms driving progression remain elusive. We discovered that the () gene is up-regulated with MPN progression in patients and required for evolution into myelofibrosis (MF) or acute myeloid leukemia (AML) in preclinical models. encodes the HMGA1 epigenetic regulators that modulate the chromatin state during embryogenesis and tissue regeneration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!